HAIFA, Israel, May 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Katherina Reiche, Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety, and Prof. Dr. Hans-Dieter Volk, Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin Germany, met with Pluristem's management and scientists on May 22, 2013. Meetings were held at the company's new manufacturing and R&D headquarters in Haifa, Israel to discuss new opportunities to strengthen existing collaborations Pluristem has with the BCRT and other German clinical research facilities.
Zami Aberman, Pluristem's Chairman and CEO, stated, "Pluristem has enjoyed a longstanding relationship with the BCRT, one of Germany's leading translational research institutions, who has conducted research for several indications using our PLX cells. We were fortunate that State Secretary Ms. Reiche and Prof. Dr. Volk were able to visit our new facility and discuss expanding our existing, valuable association in Germany."
Prof. Volk stated, "The BCRT values the affiliation we have with Pluristem and look forward expanding this collaboration in the future utilizing their exciting, innovative PLX technology."Parliamentary State Secretary Ms. Reiche stated, "Pluristem´s collaboration with BCRT is a path-breaking example of how cutting edge technologies can be translated into innovative therapies and applications. The intelligent investment in Germany and Israel into infrastructure, research and products pays off for the benefit of patients." About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.